Balanced news tone
News Sentiment
FYB sentiment intelligence
Formycon AG news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
62/100 classification confidence.
directly relevant articles
high-authority source matches
-2.2% over one week, -9.6% over four weeks, trend inactive, and near fair-value range.
Formycon AG and OneSource Specialty Pharma Announce Strategic Manufacturing Partnership for Biosimilars
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Formycon AG and OneSource Specialty Pharma Announce Strategic Manufacturing Partnership for Biosimilars
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 Jul 2026 20:38
- Source
- Market source
Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 04 Dec 2025 08:00
- Source
- PR Newswire
Formycon Ag Stock Price Forecast. Should You Buy FYB.DE?
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 22 Dec 2020 15:47
- Source
- StockInvest.us
Formycon AG: Target Price Consensus and Analysts Recommendations | FYB | DE000A1EWVY8
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 19 Aug 2020 17:22
- Source
- marketscreener.com